Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

R plasmids in Streptococcus agalactiae (group B)

T Horodniceanu, D H Bouanchaud, G Bieth

    Antimicrobial Agents and Chemotherapy
    |November 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.

    The Journal of antimicrobial chemotherapy·1997
    Same author

    A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas.

    The Journal of antimicrobial chemotherapy·1997
    Same author

    Antimicrobial activity of quinupristin-dalfopristin.

    Drugs·1996
    Same author

    Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds.

    The Journal of antimicrobial chemotherapy·1992
    Same author

    Post-antibiotic effects of RP 59500 with Staphylococcus aureus.

    The Journal of antimicrobial chemotherapy·1992
    Same author

    In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500.

    The Journal of antimicrobial chemotherapy·1992

    Two Streptococcus agalactiae plasmids conferring antibiotic resistance were isolated. One plasmid (RIP500) showed very low resistance loss, while the other (RIP501) had variable loss, impacting antibiotic resistance studies.

    Area of Science:

    • Microbiology
    • Molecular Biology
    • Genetics

    Background:

    • Antibiotic resistance in bacteria is a growing public health concern.
    • Plasmids are key genetic elements that can carry antibiotic resistance genes.
    • Streptococcus agalactiae is a significant human pathogen where plasmid-mediated resistance is relevant.

    Purpose of the Study:

    • To isolate and characterize plasmids responsible for antibiotic resistance in Streptococcus agalactiae.
    • To investigate the stability and replication control of these resistance plasmids.

    Main Methods:

    • Isolation of plasmids from Streptococcus agalactiae strains.
    • Determination of plasmid molecular weights and their percentage of total DNA.
    • Assessment of plasmid curing frequency under different conditions.

    Related Experiment Videos

  • Analysis of plasmid copy number and replication control mechanisms.

    • Main Results:

    • Two plasmids, RIP500 (tetracycline resistance) and RIP501 (chloramphenicol, erythromycin, lincomycin, pristinamycin I resistance), were identified.
    • RIP500 exhibited very low frequency of resistance loss, while RIP501 showed high and variable loss rates.
    • Plasmids RIP500 and RIP501 differed in molecular weight, DNA percentage, and copy number, suggesting distinct replication controls.

    Conclusions:

    • The characterized plasmids contribute to the antibiotic resistance profile of Streptococcus agalactiae.
    • Differential plasmid stability and replication mechanisms influence the maintenance of antibiotic resistance traits.
    • Understanding these plasmids is crucial for managing antibiotic resistance in clinical settings.